Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025

Core Insights - Helix BioPharma Corp. has filed its unaudited interim financial statements for the three-month period ending October 31, 2025, along with management's discussion and analysis and certifications from the CEO and CFO [1] Company Overview - Helix BioPharma is focused on developing innovative solutions for difficult-to-treat cancers, with a pipeline led by Tumor Defense Breaker™ L-DOS47, an antibody-enzyme conjugate aimed at enhancing therapy sensitivity in CEACAM6-expressing tumors [2] - L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its targeting foundation with the company's next-generation bi-specific antibody-drug conjugates currently in discovery [2] - The company is also advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a first-in-class oral gemcitabine prodrug designed to expand treatment options for advanced cancers [2]